Back to Search Start Over

Phase II open-label study of single-agent hydroxyurea for treatment of mast cell tumours in dogs*

Phase II open-label study of single-agent hydroxyurea for treatment of mast cell tumours in dogs*

Authors :
R. Al-Sarraf
D. B. Bailey
C. H. Zwhalen
Kenneth M. Rassnick
John D Chretin
Brenda Phillips
Source :
Veterinary and Comparative Oncology. 8:103-111
Publication Year :
2010
Publisher :
Wiley, 2010.

Abstract

This prospective study evaluated the efficacy and safety of hydroxyurea (HU) in dogs with measurable mast cell tumours (MCTs). Dogs were treated with HU at 60 mg kg(-1)per os q24h for 14 days then 30 mg kg(-1) q24h thereafter or until MCT recurrence. Forty-six dogs were enrolled. The overall response rate was 28%. Two dogs had a complete response (CR) for 256 and 448 days, respectively. Eleven dogs had a partial response for a median duration of 46 days (range, 28-189 days). Grade 2 to 4 neutropenia occurred in eight dogs and grade 4 thrombocytopenia in two. Grade 3-4 anaemia occurred in seven dogs; overall, there was a significant decrease in haematocrit after treatment with HU. The median drop in haematocrit was 10%. This study demonstrated that HU has activity in the treatment of MCTs with mild anaemia being the primary adverse event.

Details

ISSN :
14765829 and 14765810
Volume :
8
Database :
OpenAIRE
Journal :
Veterinary and Comparative Oncology
Accession number :
edsair.doi.dedup.....1313f76796deb216e6f47ece58426823
Full Text :
https://doi.org/10.1111/j.1476-5829.2010.00211.x